Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3965456rdf:typepubmed:Citationlld:pubmed
pubmed-article:3965456lifeskim:mentionsumls-concept:C0023820lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C1179435lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C0011847lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C1457869lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C0486616lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C0449297lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C1705248lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C1517004lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C1548799lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C1524073lld:lifeskim
pubmed-article:3965456lifeskim:mentionsumls-concept:C0449432lld:lifeskim
pubmed-article:3965456pubmed:issue1lld:pubmed
pubmed-article:3965456pubmed:dateCreated1985-2-15lld:pubmed
pubmed-article:3965456pubmed:abstractTextThe hypertriglyceridemia associated with streptozotocin-induced diabetes in rats is largely reflected in the plasma lipoproteins of density less than 1.006 g/ml. Analysis of the plasma apolipoproteins of these rats indicated marked alterations in both the total levels and in the lipoprotein distribution of the major apolipoproteins. In whole plasma, diabetes was associated with significant increases in apolipoprotein (apo)-AIV, apo-AI, and apo-B (mainly in the intestinally derived apo-B240) and a marked decrease in apo-E. In the d less than 1.006 g/ml lipoprotein fraction (very-low-density lipoproteins (VLDL], there were significant increases in apo-B240, apo-AI, and apo-AIV and decreased levels of apo-E and the C apolipoproteins. The decrease in apo-C was primarily due to lower levels of apo-CII, and the ratio of the lipoprotein lipase inhibitor, apo-CIII, to the lipoprotein lipase activator, apo CII, was significantly increased over that in controls. The comparative clearance of triglycerides of VLDL particles from control and diabetic rat plasma was tested in recirculating heart perfusion in vitro. During 45-min perfusions of hearts from control donor rats, lipolysis of triglycerides of VLDL from diabetic rats was only 63-64% of that using plasma VLDL from control rats. Perfusion of hearts from diabetic rats with VLDL from control rats gave lipolysis values of only 53% of that obtained with normal hearts. Where both the VLDL and hearts were obtained from diabetic rats, lipolysis was 23% of that observed when both the lipoprotein and the organ were from control rats. The data suggest that in addition to depressed lipoprotein lipase activity in the tissue from diabetic rats, there are also major compositional changes in circulating lipoproteins which may contribute to defective triglyceride clearance from the circulation.lld:pubmed
pubmed-article:3965456pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:languageenglld:pubmed
pubmed-article:3965456pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:citationSubsetIMlld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965456pubmed:statusMEDLINElld:pubmed
pubmed-article:3965456pubmed:monthJanlld:pubmed
pubmed-article:3965456pubmed:issn0021-9258lld:pubmed
pubmed-article:3965456pubmed:authorpubmed-author:VahounyG VGVlld:pubmed
pubmed-article:3965456pubmed:authorpubmed-author:IrwinDDlld:pubmed
pubmed-article:3965456pubmed:authorpubmed-author:BriscoePPlld:pubmed
pubmed-article:3965456pubmed:authorpubmed-author:O'LooneyPPlld:pubmed
pubmed-article:3965456pubmed:issnTypePrintlld:pubmed
pubmed-article:3965456pubmed:day10lld:pubmed
pubmed-article:3965456pubmed:volume260lld:pubmed
pubmed-article:3965456pubmed:ownerNLMlld:pubmed
pubmed-article:3965456pubmed:authorsCompleteYlld:pubmed
pubmed-article:3965456pubmed:pagination428-32lld:pubmed
pubmed-article:3965456pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:meshHeadingpubmed-meshheading:3965456-...lld:pubmed
pubmed-article:3965456pubmed:year1985lld:pubmed
pubmed-article:3965456pubmed:articleTitleLipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes.lld:pubmed
pubmed-article:3965456pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3965456pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3965456pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965456lld:pubmed